Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells.

Homologous recombination (HR)-deficient cancers are sensitive to inhibitors of Poly-ADP Ribose Polymerase (PARPi), which have shown clinical efficacy in the treatment of high-grade serous cancers (HGSC). However, the majority of patients will relapse, and acquired PARPi resistance is emerging as a p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Färkkilä, Anniina, Rodríguez, Alfredo, Oikkonen, Jaana, Gulhan, Doga C., Nguyen, Huy, Domínguez, Julieta, Ramos, Sandra, Mills, Caitlin E., Pérez-Villatoro, Fernando, Lazaro, Jean-Bernard, Zhou, Jia, Clairmont, Connor S., Moreau, Lisa A., Park, Peter J., Sorger, Peter K., Hautaniemi, Sampsa, Frias, Sara, D’Andrea, Alan D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8323804/
https://ncbi.nlm.nih.gov/pubmed/33514515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-2912
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados